AZD8848 (n = 26) | Placebo (n = 25) | All (n = 51) | |
---|---|---|---|
Patients with an AEa, n (%) | |||
Any AEs | 22 (85) | 22 (88) | 44 (86) |
Fatal SAEs | 0 | 0 | 0 |
Non-fatal SAEs | 0 | 1 (4) | 1 (2) |
DAEsb | 4 (15) | 2 (8) | 6 (12) |
Other significant adverse events | 0 | 0 | 0 |
Total number of adverse eventsc, n | |||
Any adverse events | 84 | 94 | 178 |
Maximum intensity | |||
Mild | 65 | 70 | 135 |
Moderate | 16 | 23 | 39 |
Severe | 3 | 1 | 4 |
Maximum AEs/patient | 8 | 9 | 9 |
Causally related AEsd | 22 | 11 | 33 |
SAEs (fatal and non-fatal) | 0 | 1 | 1 |
Causally related SAEs (fatal and non-fatal)d | 0 | 1 | 1 |
DAEs | 9 | 2 | 11 |
Other significant adverse events | 0 | 0 | 0 |